Nurses prepare patients’ treatments in the pharmacy of the ambulatory ward at the National Centre for Tuberculosis and Lung Disease in Georgia’s capital, Tbilisi. (Daro Sulakauri/MSF)
Testing novel, short, all-oral regimens for MDR-TB
Médecins Sans Frontières (MSF), Partners In Health (PIH), Interactive Research and Development (IRD), and their partners have launched two major clinical trials which seek to revolutionize treatment for the toughest strains of tuberculosis (TB), the world’s leading infectious disease killer.
The two clinical trials are sponsored by MSF. The Principal Investigators are Drs. Carole Mitnick (Harvard Medical School) and Lorenzo Guglielmetti (MSF).
Why these clinical trials?
Current treatments for MDR-TB are long (up to 24 months), ineffective (only 56% succeed) and often cause terrible side effects, including acute psychosis and permanent deafness. All the while, patients ingest up to 14,000 pills and some of them have to endure months of painful, daily injections. Moreover, the costliness, difficulty and length of current treatments make them hard to implement in many high-burden countries.
To address the problem, the two clinical trials use the first TB drugs developed in almost 50 years — bedaquiline and delamanid — to find radically shorter (6 or 9 months), more tolerable, injection-free treatments for MDR-TB.
1. Clinical trial for fluoroquinolone-susceptible MDR-TB (endTB clinical trial)
The clinical trial was expected to enroll 750 patients across eight countries: Georgia, India, Kazakhstan, Lesotho, Pakistan, Peru and South Africa. These are all countries with significant TB burdens, where MSF, PIH or IRD support local MDR-TB treatment activities.
As of October 2021, there were 754 patients enrolled.
This is a randomized, controlled, Phase III clinical trial testing five new, all oral, 9-month regimens compared to the current standard of care. Randomization will be outcome adapted, rather than fixed. This means that the probability of being randomized to regimens changes as the outcomes are reported: more patients will be assigned to regimens that are producing better outcomes.
Study treatment regimens
Each experimental regimen will contain at least one new drug, in combination with up to four companion drugs. The control regimen is the local standard of care consistent with latest WHO recommendations and may include new drugs if indicated.
2. Clinical trial for fluoroquinolone-resistant MDR-TB (endTB-Q clinical trial)
The clinical trial is expected to enroll 324 patients across five countries (India, Lesotho, Pakistan, Peru, Vietnam, and Kazakhstan) to find simpler, less toxic, shorter regimen for rifampin- and fluoroquinolone-resistant tuberculosis.
As of May 2022, there are 201 patients enrolled.
This is a randomized, controlled, Phase III clinical trial testing a new, all oral regimen compared to the current standard of care.
Study treatment regimens
The experimental regimen will contain bedaquiline, delamanid, clofazimine, and linezolid, and will be delivered for 24 or 39 weeks. endTB-Q adopts a personalized medicine approach, by individualizing the treatment duration based on baseline characteristics and treatment response of each participant.
Control-arm treatment will be constructed and delivered according to local standard of care and consistent with latest WHO guidelines and may include bedaquiline and/or delamanid in addition to other drugs.
*Standard of Care (SOC) control, composed according to WHO guidelines, including the possible use of Bedaquiline and Delamanid
Several independent groups provide formal external oversight of the study protocols, implementation, operation and analysis:
- Institutional Review Boards or Ethics Committees at MSF, Harvard Medical School, IRD, Antwerp Institute of Tropical Medicine, and in each country participating in the clinical trial
- Independent Scientific Advisory Committee (SAC)
- WHO Ethics Review Committee (for endTB-Q)
- Global Community Advisory Board, convened by the Treatment Action Group
- Data Safety and Monitoring Board (DSMB)
These groups will continue to assure the relevance of the trials for clinical care and policy, their safety for participants, and that global standards for clinical research are met or exceeded.